Literature DB >> 23065031

Identification of factors associated with cancer related fatigue syndrome in disease-free breast cancer patients after completing primary treatment.

Ollie Minton1, Susanna Alexander, Patrick Charles Stone.   

Abstract

This study is an analysis of variables associated with women who meet the criteria for after completion of successful primary treatment for breast cancer. This analysis was conducted to identify factors independently associated with cancer related fatigue syndrome using a combined dataset from two non-overlapping studies conducted on similar populations. Participants who were clinically (and radiologically) disease-free, between 3 months and 2 years after treatment, were recruited from a single centre. A diagnostic interview was conducted to ascertain whether they met the criteria for cancer related fatigue syndrome. We analysed a number of treatment, laboratory and questionnaire variables between groups. Those that were significantly different were entered into a logistic model. A total of 278 subjects (105 cases of cancer related fatigue syndrome and 173 controls who did not meet the criteria) were analysed. A number of questionnaire responses were significantly different including all of the European Organisation for the Research and Treatment of Cancer core 30 item quality of life questionnaire (EORTC QLQ c30) and Breast questionnaire 23 item subgroup scores. 11 variables were entered into the final model and 5 were independently associated with cancer related fatigue syndrome: Hospital anxiety and depression scale score, EORTC pain and insomnia scales, breast systemic side effects and plasma sodium. There was, however, no association with demographic or treatment variables. As a conclusion, cancer related fatigue syndrome after treatment is linked with sub-clinical mood pain and subjective sleep disturbance and with the side effects of systemic treatment. This study is unable to determine whether these associations are causal, but they provide a potential target for interventions to manage the symptoms of cancer related fatigue syndrome.

Entities:  

Mesh:

Year:  2012        PMID: 23065031     DOI: 10.1007/s10549-012-2284-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice.

Authors:  John Wong; Lisa T Tran; Kaari A Lynch; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2017-12-12       Impact factor: 4.742

2.  Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida.

Authors:  Sara Vargas; Michael H Antoni; Charles S Carver; Suzanne C Lechner; William Wohlgemuth; Maria Llabre; Bonnie B Blomberg; Stefan Glück; Robert P DerHagopian
Journal:  Int J Behav Med       Date:  2014-12

3.  Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.

Authors:  Diana M Norden; Raymond Devine; Sabahattin Bicer; Runfeng Jing; Peter J Reiser; Loren E Wold; Jonathan P Godbout; Donna O McCarthy
Journal:  Physiol Behav       Date:  2014-12-30

4.  Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study.

Authors:  Anita R Peoples; Joseph A Roscoe; Robert C Block; Charles E Heckler; Julie L Ryan; Karen M Mustian; Michelle C Janelsins; Luke J Peppone; Dennis F Moore; Charlotte Coles; Karen L Hoelzer; Gary R Morrow; Ann M Dozier
Journal:  Support Care Cancer       Date:  2016-12-20       Impact factor: 3.603

5.  Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change.

Authors:  Chad W Wagoner; Jordan T Lee; Erik D Hanson; Zachary Y Kerr; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini
Journal:  Breast Cancer       Date:  2022-06-24       Impact factor: 3.307

6.  Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice.

Authors:  Diana M Norden; Donna O McCarthy; Sabahattin Bicer; Raymond D Devine; Peter J Reiser; Jonathan P Godbout; Loren E Wold
Journal:  Life Sci       Date:  2015-10-20       Impact factor: 5.037

7.  Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function.

Authors:  Diana M Norden; Sabahattin Bicer; Yvonne Clark; Runfeng Jing; Christopher J Henry; Loren E Wold; Peter J Reiser; Jonathan P Godbout; Donna O McCarthy
Journal:  Brain Behav Immun       Date:  2014-08-04       Impact factor: 7.217

8.  Well-being of newly diagnosed women with breast cancer: which factors matter more?

Authors:  Rugilė Ivanauskienė; Žilvinas Padaiga; Renata Šimoliūnienė; Giedrė Smailytė; Auksė Domeikienė
Journal:  Support Care Cancer       Date:  2013-10-18       Impact factor: 3.603

9.  Ganoderic acid alleviates chemotherapy-induced fatigue in mice bearing colon tumor.

Authors:  Abudumijiti Abulizi; Ling Hu; Ang Ma; Fang-Yu Shao; Hui-Ze Zhu; Si-Mei Lin; Guang-Ying Shao; Yue Xu; Jian-Hua Ran; Jing Li; Hong Zhou; Dong-Mei Lin; Lian-Fu Wang; Min Li; Bao-Xue Yang
Journal:  Acta Pharmacol Sin       Date:  2021-04-29       Impact factor: 7.169

Review 10.  Effects of mindfulness-based interventions on fatigue in cancer survivors: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Shelley A Johns; Will L Tarver; Ekin Secinti; Catherine E Mosher; Patrick V Stutz; Jennifer L Carnahan; Tasneem L Talib; Mackenzie L Shanahan; Micah T Faidley; Kelley M Kidwell; Kevin L Rand
Journal:  Crit Rev Oncol Hematol       Date:  2021-03-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.